Abstract
The development of new drugs capable of treating or alleviating the symptoms of Alzheimer's diseases become a global goal in the last few years. The rapid, uncontrolled and devastating progression of the Alzheimer disease has been affecting over 55 million patients worldwide, representing over 270 billion U$ in cost. Nonetheless, the limited effective drugs, capable just to restrict and temporally control the progression of the disease, also remain a drawback and increase the urgency o new therapies. In this direction, we have fully developed, characterized and evaluated nanomicelles of taurine against the formation of beta amyloid plaque as the safety use. The results demonstrated that the nanomicelles were capable to reduce the beta amyloid plaque as a safety profile in healthy cells. Although preliminary, the results provides evidences that taurine nanomicelles are effective in the treatment of Alzheimer diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
